Global Antisense and RNAi Therapeutics Market 2019-2023| High Target Affinity and Specificity of RNAi Therapeutics| Technavio
LONDON--(BUSINESS WIRE)--Nov 30, 2018-- analysts forecast the global antisense and RNAi therapeutics market to grow at a CAGR of close to 9% during the forecast period, according to their latest market research report.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181130005142/en/
Technavio analysts forecast the global antisense and RNAi therapeutics market to grow at a CAGR of close to 9% by 2023. (Graphic: Business Wire)
The potential to address multiple therapy areas is one of the major trends being witnessed in the . Antisense and RNAi therapeutics can regulate the expression of genes inside the cells. They involve the use of short sequences of the nucleic acids (DNA and RNA), often termed as oligonucleotides, which can inhibit the expression of a specific gene product.
According to Technavio analysts, one of the key factors contributing to the growth of the global antisense and RNAi therapeutics market is the high target affinity and specificity of RNAi therapeutics:
Global antisense and RNAi therapeutics market: Ease of standardization and large-scale manufacturing
Conventional manufacturing processes are used to manufacture protein and nucleic acid-based therapies on a large scale. These processes are highly complex and are not standardized. The introduction of advanced manufacturing platforms by companies has created an in-house standardized system for calling up nucleic acid products. For instance, synthetic genomics has engineered and RNA replicon platform by which a single-liter bioreactor is able to produce more than five million doses of the company’s RNA therapy.
According to a senior analyst at Technavio, “GE Healthcare has introduced a standardized procedure for scaling up and optimizing siRNA. The siRNA molecules were scaled up 16-fold to 1.52 mmol using an initial scale of 95 umol in an AKTA oligopilot 100 system. Therefore, advances that enable the manufacture of large quantities of products have encouraged many companies to invest in the antisense and RNAi therapeutics market.”
Global anesthesia disposables market: Segmentation analysis
The global antisense and RNAi therapeutics market research report provides market segmentation by type (antisense therapy and RNAi therapy), by application (cancer, metabolic disorders, and cardiovascular diseases), and by region (the Americas, EMEA, and APAC). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Of the two major types, the antisense therapy segment held the largest market share in 2018, contributing close to 76% of the market. This antisense therapy segment will dominate the global market throughout the forecast period.
The Americas held the largest share of the market in 2018, accounting for close to 63% share. It was followed by EMEA and APAC respectively. The presence of key vendors such as Alnylam Pharmaceuticals, Bausch Health, Biogen, and Ionis pharmaceuticals in the US is a major reason for the huge market share of the Americas in the global market.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Market LandscapeMarket ecosystem Market characteristics Market segmentation analysis
Market SizingMarket definition Market size and forecast
Five Forces Analysis
Geographical SegmentationRegional comparison Key leading countries
Vendor LandscapeVendors covered Vendor classification Market positioning of vendors Competitive scenario
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20181130005142/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 11/30/2018 09:01 AM/DISC: 11/30/2018 09:01 AM